Riskpilot← Back to searchSign inGet full accessAlphraMedic AB
ABActiveOrg 5569526402Kämpevägen 17Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20133 employees
Revenue 2025
SEK 5,3M
-9% vs 2024
EBITDA margin
5.2%
-73% vs 2024
Equity ratio
83.1%
Financial strength
Net profit 2025
SEK 213K
-74% vs 2024
| Revenue | SEK 5,3M | -9% |
| EBITDA | SEK 276K | -73% |
| Net profit | SEK 213K | -74% |
| Total assets | SEK 3,7M | +8% |
| Equity | SEK 3,1M | +0% |
| Employees | 3 | — |
Legal name
AlphraMedic AB
Org number
5569526402
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
9 december 2013
Share capital
SEK 50 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att bedriva tillverkning och försäljning av medicinsk utrustning och medicintekniska produkter samt därmed förenlig verksamhet.
Address
Kämpevägen 17
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 3 260 | 4 026 | 4 201 | 5 767 | 5 275 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 502 | 625 | 532 | 1 027 | 276 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 502 | 625 | 532 | 1 027 | 276 |
| Net financials | −1 | — | 1 | 23 | 2 |
| Profit before tax | 501 | 625 | 533 | 1 050 | 278 |
| Tax | −108 | −135 | −117 | −224 | −65 |
| Net profit | 393 | 490 | 416 | 826 | 213 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 158 | 2 530 | 2 968 | 3 396 | 3 678 |
| Equity | 1 914 | 2 204 | 2 620 | 3 046 | 3 058 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 244 | 326 | 348 | 351 | 619 |
| Total debt | 244 | 326 | 348 | 351 | 619 |
EBITDA margin
5.2%
This company
15.8%
Market median
-67% vs market
20212025
Equity ratio
83.1%
This company
38.2%
Market median
+118% vs market
20212025
Return on equity
7.0%
This company
18.4%
Market median
-62% vs market
20212025
Net profit margin
4.0%
This company
8.1%
Market median
-51% vs market
20212025
Asset turnover
1.43×
This company
1.12×
Market median
+28% vs market
20212025
Debt / equity
0.20×
This company
0.62×
Market median
+68% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ME | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of AlphraMedic AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Martin Erik Holger Knuthsson | Audit | 0 companies |
| Jan Gösta Vilhelm Franzén | Board of Directors | 0 companies |
| Ann-Kristine Viktoria Davidsson | Deputy Board Member | 0 companies |